One platform for precision oncology

At Tempus, we are changing the way precision oncology care is delivered. By leveraging clinical and molecular data, we offer comprehensive genomic profiling services, including hereditary testing, minimal residual disease and monitoring, and therapy selection, transforming the way cancer is diagnosed and treated.

Our single platform is a one-stop-shop for all your cancer testing needs, with a comprehensive portfolio and a vast multimodal database, we are making precision medicine a reality for patients everywhere.

Forging a new path in precision oncology


Maximize biomarker detection and identify more clinically actionable variants linked to targeted therapy options.

In a metastatic pan-cancer analysis of 1,448 patients with actionable variants, 9% of patients had unique actionable alterations found in liquid biopsy that were not detected in solid tumor alone.1

image description
The value of dual, solid tumor and liquid biopsy NGS testing Read more


Enable a more complete understanding of clinically actionable fusions and altered splicing.

29% more patients, within a cohort of patients that had fusions discovered, were identified with a unique, clinically actionable fusion that matched to a targeted therapy with addition of RNA sequencing, compared to DNA sequencing alone.2

image description
The value of RNA sequencing Read more


Provides accurate insight through true identification of somatic alterations and maximizes targeted therapy opportunities.

28% reduction in somatic false-positive calls, improving accuracy compared to a tumor-only analysis.3

image description
The clinical benefits of tumor + normal match sequencing Watch now


Offering a portfolio of MRD and monitoring assays.

Finely tuned tumor-naive assay to help detect residual disease or recurrence in colorectal cancer.

Ultra sensitive, whole genome tumor-informed assay that enables detection of ctDNA at very low levels in NSCLC, breast cancer and for IO treatment response monitoring.


Expansive and developing portfolio of algorithmic testing capabilities and digital pathology platform leveraging ~6M de-identified research records.

Tempus One: the first step toward artificial intelligence enabled genomic reporting, to help you make data-driven precision medicine decisions.

image description
Tempus One Read more


Providing a comprehensive view of your patient’s molecular profile.

Identify patients with hereditary risk through streamlined cancer testing.

image description
The value of integrated clinical-molecular data Read more


As part of our genomic sequencing portfolio, Tempus offers a comprehensive menu of add-on IHC offerings.

  • PD-L1 Clones:
    • PD-L1 22C3 (default option, unless a different clone is selected)
    • PD-L1 28-8
    • PD-L1 SP142
    • PD-L1 SP263
  • MMR (MLH1, MSH2, MSH6, PMS2)
  • CLDN18
  • Powered by NeoGenomics:
      • HER2 with reflex to ERBB2 FISH for breast and gastric cancers*
      • HER2 IHC only (for other cancer types)
      • FOLR1 (FRɑ)

*In accordance with appropriate ASCO/CAP and NCCN guidelines, your order will be reflexed based on the IHC scores listed for the breast or gastric cancer type4-7. HER2 testing is recommended for patients with metastatic colorectal cancer (CRC). CRC specimens are not scored in accordance with CRC guidelines8,9, but instead fall under the HER2 gastric scoring criteria and remain candidates for FISH reflex
Offered under early access only

Our comprehensive test offerings

  • xT

Solid Tumor + Normal Match

648 gene DNA sequencing panel

MSI Status, TMB

—IHC analysis of PD-L1 and MMR proteins, CLDN18, HER2 (powered by NeoGenomics), and FOLR1 (powered by NeoGenomics)

  • xR

Solid Tumor + Hematologic Malignancies

Whole-transcriptome RNA sequencing panel

—IHC analysis of PD-L1 and MMR proteins, CLDN18, HER2 (powered by NeoGenomics), and FOLR1 (powered by NeoGenomics)

  • xT

Hematologic Malignancies

648 gene DNA sequencing panel

  • xF
  • xF+

Liquid Biopsy

105/523 gene ctDNA sequencing panel

MSI-H status, bTMB

  • xG
  • xG+

Hereditary Cancer Test (Powered by Ambry Genetics®)

36/77 gene panels for hereditary cancers

  • xE

Whole Exome

19,000+ gene DNA sequencing panel


—IHC analysis of PD-L1 and MMR proteins

  • xM

Portfolio of MRD & Monitoring Assays

Tumor-naive and tumor-informed assays to detect residual disease or early cancer recurrence in select cancers along with IO treatment response monitoring.

Algorithmic Tests

TO, HRD, DPYD, UGT1A1, PurIST℠, Merlin

Introducing xM, our new portfolio of MRD assays.

Learn more about xM

Ordering flexibility to help optimize your workflow

Tempus Hub

View interactive and in-depth next-generation sequencing results in the context of a patient’s clinical history, filterable treatment applications and clinical trials, derived from our vast library of molecular profiling data.

To access the Hub platform, visit hub.securetempus.com, and select the “Request Access” button.

Available on both desktop and mobile devices.

Learn more
image description

EHR Integration

Take advantage of Tempus’ rapidly growing multimodal dataset capabilities to structure, unify, and normalize your data for clinical trial matching, precision medicine analytics, publications, and AI development.

Learn more
image description

Mobile Phlebotomy

We want to make blood draw services as convenient as possible for your patients. For patients unable to visit a clinic, we can help to schedule a blood draw appointment at a location convenient to them.

To schedule an appointment, please call 800.739.4137 or utilize the Mobile Phlebotomy Request Form.

image description
Financial Assistance

We help provide access to our tests for all patients in financial need

Approval of the financial assistance application is based on your household income and takes into account all life circumstances. Once a financial assistance application is submitted either online or over the phone, you will receive a decision at the time of submission. 

  • Step 1

    Apply for financial assistance online at access.tempus.com.

  • Step 2

    If approved, you will know immediately about the maximum out-of-pocket cost of your testing.

  • Step 3

    Please contact billing@tempus.com if you are concerned about out-of-pocket costs and would like to discuss your options.

    All U.S.-based patients are eligible to apply for financial assistance regardless of insurance status. For uninsured and international patients, we offer a self-pay option. If you have any questions, please email patients@tempus.com.

Notice and Authorization for Medical Records

Tempus is working to make precision medicine a reality for cancer patients. Each person’s cancer and medical circumstances are unique. Tempus has a database of de-identified health information from many cancer patients. We believe we can improve cancer care and research, in the United States and abroad, by adding more de-identified health information to our database.

Through access.tempus.com, you will be directed to our Notice and Authorization for Medical Records authorization form. This optional form allows us to request outcomes and other medical records from your health care providers. Please see the Notice and Authorization for Medical Records form for more information.

Offered under early access only

  1. Based on a retrospective study involving a cohort of randomly selected patients with breast, colorectal, lung, and prostate cancer. Iams, WT, MacKay M, Ben-Shachar R, et al. Concurrent tissue and circulating tumor DNA molecular profiling to detect guideline-based targeted mutations in a multicancer cohort. JAMA Netw Open. 2024. Clinically actionable variants were identified using indication-matched recommendations from NCCN guidelines.
  2. Based on a retrospective study involving a cohort of randomly selected patients with tumor types including low grade glioma, sarcoma, glioblastoma, bladder, NSCLC and biliary tract cancer, where a fusion was detected in 2.5% of samples overall (n=2,156/84,938). Michuda J, Park BH, Cummings AL, et al. Use of clinical RNA-sequencing in the detection of actionable fusions compared to DNA-sequencing alone. J Clin Oncol. 2022;40(16_suppl):3077.
  3. Based on a retrospective study involving a cohort of randomly selected patients with tumor types including brain, breast, colorectal, lung, ovarian, endometrial, pancreatic and prostate cancer. Beaubier N, Bontrager M, Huether R, et al. Integrated genomic profiling expands clinical options for patients with cancer. Nat Biotechnol. 2019;37(11):1351-1360
  4. NCCN Clinical Practice Guidelines in Oncology. Breast. Version 2.2024.
  5. Wolff AC, Somerfield MR, Dowsett M, et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists guideline update. J Clin Oncol. 2023;41(22):3867-3872.
  6. NCCN Clinical Practice Guidelines in Oncology. Gastric. Version 1.2024.
  7. Bartley AN, Washington MK, Ventura CB, et al. Her2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Arch Pathol Lab Med. 2016;140(12):1345-1363.
  8. NCCN Clinical Practice Guidelines in Oncology. Colon Cancer. Version 1.2024.
  9. NCCN Clinical Practice Guidelines in Oncology. Rectal Cancer. Version 1.2024.
  10. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). ©National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed [3.16.24].

This is data-driven precision medicine

This is the future of healthcare.